AR Inhibition Achieves Responses in AR+ Triple-Negative Breast Cancer [Clinical Trials]

The AR inhibitor enzalutamide achieved responses in patients with advanced TNBC in a phase II trial.

from Cancer via ola Kala on Inoreader https://ift.tt/2pYwhdY
via IFTTT